Glutaminase inhibition in renal cell carcinoma therapy

Aleksandra Maria Raczka, Paul Andrew Reynolds

Research output: Contribution to journalReview articlepeer-review

14 Citations (Scopus)
7 Downloads (Pure)


Receptor tyrosine kinase inhibitors have been a standard first-line therapy for renal cell carcinoma (RCC) for over a decade. Although they stabilize the disease, they are unable to remove all tumor cells, leading to relapse. Moreover, both intrinsic and acquired resistance to therapy are a significant health burden. In order to overcome resistance, several combination therapies have been recently approved by the FDA. Another approach takes advantage of altered metabolism in tumor cells, which switch to alternative metabolic pathways to sustain their rapid growth and proliferation. CB-839 is a small molecule inhibitor of kidney type glutaminase (GLS). GLS is often upregulated in glutamine addicted cancers, enhancing glutamine metabolism for the production of energy and the biosynthesis of various cellular building blocks. CB-839 is currently in clinical trials for several tumors, including clear cell (cc)RCC, both as monotherapy and in combination with the approved therapeutic agents everolimus, cabozantinib and nivolumab. Early results of Phase 1/2 clinical trials look promising, especially for CB-839 plus cabozantinib, and all combinations seem to be well tolerated. However, cancer cells can activate compensatory pathways to overcome glutaminolysis inhibition. Therefore, genetic and metabolomic studies are crucial for the successful implementation of CB-839 alone or in combination in subgroups of ccRCC patients.
Original languageEnglish
Number of pages9
JournalCancer Drug Resistance
Publication statusPublished - 14 May 2019


  • Glutamine addiction
  • Renal cell carcinoma (RCC)
  • Combination therapy
  • Metabolism


Dive into the research topics of 'Glutaminase inhibition in renal cell carcinoma therapy'. Together they form a unique fingerprint.

Cite this